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Abstract
Background: Culicoides hypersensitivity (CH) is induced in horses by salivary allergens of Culicoides midges. In
Iceland, the causal Culicoides species for CH are not present. Previous epidemiological data indicated that Icelandic
horses are more susceptible to CH when they are exported from Iceland and first exposed to Culicoides at adult
age. Horses born in countries where Culicoides is endemic, develop the disease less frequently. Here, we established
a longitudinal allergy model to identify predictive and diagnostic serological biomarkers of CH.
Results: Sixteen adult Icelandic horses from Iceland were imported to the Northeastern United States (US) during
the winter and were kept in the same environment with natural Culicoides exposure for the next two years. None
of the horses showed clinical allergy during the first summer of Culicoides exposure. In the second summer, 9/16
horses (56%) developed CH. Allergen specific IgE and IgG isotype responses in serum samples were analysed using
nine potential Culicoides allergens in a fluorescent bead-based multiplex assay. During the first summer of Culicoides
exposure, while all horses were still clinically healthy, Cul o 2 specific IgG3/5 antibodies were higher in horses that
developed the allergic disease in the second summer compared to those that did not become allergic (p = 0.043).
The difference in Cul o 2 specific IgG3/5 antibodies between the two groups continued to be detectable through
fall (p = 0.035) and winter of the first year. During the second summer, clinical signs first appeared and Cul o 3
specific IgG3/5 isotypes were elevated in allergic horses (p = 0.041). Cul o 2 specific IgG5 (p = 0.035), and Cul o 3
specific IgG3/5 (p = 0.043) were increased in late fall of year two when clinical signs started to improve again.
Conclusions: Our results identified IgG5 and IgG3/5 antibodies against Cul o 2 and Cul o 3, respectively, as markers
for CH during and shortly after the allergy season in the Northeastern US. In addition, Cul o 2 specific IgG3/5
antibodies may be valuable as a predictive biomarker of CH in horses that have been exposed to Culicoides but did
not yet develop clinical signs.
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Background
Culicoides hypersensitivity (CH) is an allergic disease in
adult horses known by several names, such as summer
eczema, sweet itch, summer seasonal recurrent derma-
titis, insect bite hypersensitivity, and others [1, 2]. CH is
an immunoglobulin E (IgE) mediated type-I hypersensi-
tivity caused by bites of Culicoides midges [3–5]. Af-
fected horses develop a seasonal recurrent allergic
dermatitis. Clinical signs start in spring or early summer
while Culicoides are present in the environment and in-
clude pruritus, loss of hair, skin irritation, and open
wounds. The initially acute dermatitis develops into
chronic skin lesions during the summer and as long as
the horses are continuously exposed to Culicoides in
their environment [3, 5–7]. Skin lesions typically occur
at the preferred feeding sites of Culicoides, can differ by
geographic location and species of the midges, and can
generally include the ventral midline, head, chest, neck,
mane, and tail, and other skin areas [7]. Due to the ex-
treme discomfort of CH, severely affected horses kept
on pasture experience weight loss during the summer
while their herd mates gain weight. Clinical signs start to
improve in fall with decreasing Culicoides exposure and
can solve completely during the winter. Although CH is
not a life-threatening disease, it massively affects the
well-being and performance of the affected horses for an
extended time during the summer [2, 8].
CH affects all breeds of horses although the prevalence
is highly variable (4–70%) [9–13]. The risk of developing
the allergic condition is particularly high for adult Ice-
landic horses born in Iceland after export to countries
where Culicoides is endemic [14, 15]. Culicoides species
feeding on horses have not been found in Iceland [5, 7,
16]. Exported adult Icelandic horses often develop clin-
ical allergy during their second summer of exposure to
Culicoides midges [5, 7].
The allergic skin reaction can be transferred to healthy
horses by intradermal (i.d.) injection of IgE from allergic
individuals followed by i.d. injection of Culicoides extract
[3]. In addition to IgE, the involvement of IgG3/5 in Fc-
receptor-mediated degranulation of equine mast cells
has been discussed [3, 4, 6, 7]. In particular, one mono-
clonal antibody (mAb) against equine IgG3/5, clone
CVS40, provoked immediate skin reaction after i.d. in-
jection [3, 4]. However, i.d. injection of several other
mAbs against IgG3/5, IgG5 or IgG1/3 did not induce
any skin reaction [4].
Salivary proteins of Culicoides midges can cause the
allergic reaction by cross-linking allergen specific IgE on
the surface of skin mast cells in affected horses [3, 4, 17,
18]. Several salivary proteins from different Culicoides
species, such as C. nubeculosus, C. obsoletus, and C.
sonorensis, have been identified as potential allergens by
various groups [6, 10, 19–22]. The classification of these
proteins as major and minor allergens of CH still has to
be confirmed for various region and environments
around the world.
Culicoides midges are active from early summer to fall
[5, 7]. During the winter months, when midges are ab-
sent from the environment, clinical allergy wanes and
CH affected horses get a temporary relief from clinical
signs until horses are exposed again to Culicoides [4, 5].
All current treatment options of CH are symptomatic,
offering at best temporary relief but do not cure the al-
lergic condition. Tests or biomarkers to identify horses
that may develop CH at an early stage and prior to clin-
ical allergy do not yet exist.
Here, we established a longitudinal CH model in
horses that were exported from Iceland to the United
States of America (US) during the winter and were kept
for the following two years in a defined environment
with natural exposure to Culicoides. Serum samples were
obtained from the horses at several times to identify
serum biomarkers as predictors and indicators of clinical
allergy (Fig. 1). Clinical signs were recorded during the
two-year study period and allowed the grouping of the
horses into allergic and non-allergic individuals. Serum
samples were analysed for allergen specific IgG isotypes
and IgE using a new allergen multiplex assay with nine
potential Culicoides salivary allergens. Allergen specific
IgG and IgE data were then analysed by asking the fol-
lowing questions: 1) Can allergen specific IgG or IgE dis-
tinguish between allergic and non-allergic horses prior
to the development of clinical signs of CH? 2) Are there
any differences detectable between the two groups prior
to the first Culicoides allergen exposure? 3) Which aller-
gen specific IgG or IgE combinations can be used to dif-
ferentiate between allergic and non-allergic horses while
clinical signs of CH are present? and 4) Can allergen
specific IgG or IgE isotypes differentiate between allergic
and non-allergic groups after CH first occurred and
while clinical signs were not apparent anymore (e.g. during
the winter)?
Results
Development of clinical allergy
All 16 Culicoides naïve horses included in this two-year
study remained clinically healthy during the first sum-
mer of natural Culicoides exposure. Several horses
started to occasionally rub their mane and/or tail and
mild alopecia was observed at the face or chest resulting
in a slight elevation of their clinical scores during their
first summer in the US. During the second summer after
import, the horses were again exposed to Culicoides.
Seven horses remained clinically healthy showing the
same slight increase in their clinical scores as in year 1,
while nine horses (56%) developed clinical allergy
including dermatitis (Fig. 2).
Raza et al. BMC Veterinary Research          (2020) 16:283 Page 2 of 12
Clinical signs of allergy were observed between early
June and mid-October of year 2 (all p < 0.0001), coincid-
ing with the seasonal presence of Culicoides in the envir-
onment of the horses (Fig. 3a). Allergic horses were
affected on the face, their intermandibular space, chest
and/or ventral midline. Several horses showed loss of
hair at the mane and/or tail (Fig. 2). After the first frost
mid-October, clinical signs resolved and clinical scores
in allergic horses became again comparable to the non-
allergic group. However, the allergic episode during the
summer was still visible in some horses for another 1–2
months depending on allergy severity of the individual
horse. In allergic horses, mane and tail hair were grow-
ing back in fall while dry skin crusts were still found at
the previous locations of dermatitis. The comparison of
average monthly high and low environmental
temperature between years 1 and 2 did not show differ-
ences between years, with the exception of slightly ele-
vated temperatures in March of year 1 (Fig. 3b).
The group assignments into allergic and non-allergic
horses were based on the occurrence of clinical signs of
allergy in the second summer of Culicoides exposure.
The group assignment was applied to the entire two-
year observation period of this study to identify possible
differences in allergen specific antibody responses be-
tween the two groups.
Serological predictors of clinical allergy
Allergen specific IgG isotype responses were measured
in serum samples from the horses using a Culicoides al-
lergen multiplex assay based on nine potential salivary
allergens. Our longitudinal model allowed us to analyze
if individual allergen specific isotypes distinguished aller-
gic from non-allergic horse as potential predictive
markers of CH before horses developed clinical allergy
in year 2. Allergen specific antibodies in serum samples
taken while the horses were still in Iceland (October
prior to import) or in spring (March) of year 1 after im-
port to the US but prior to Culicoides exposure were
overall low and did not result in serological differences
that could separate the two groups (Figs. 4 and 5).
During their first summer in the US all horses were
exposed to Culicoides midges and responded with in-
creased serum antibodies against Culicoides salivary al-
lergens. Nevertheless, clinical signs of allergy were not
observed. In August of year 1, Cul o 2 specific IgG3/5
serum antibodies increased significantly in the allergic
group (p = 0.043) compared to non-allergic horses
(Fig. 4). After the Culicoides exposure season in Novem-
ber of year 1, Cul o 2 specific IgG3/5 antibodies were
Fig. 1 Experimental outline of the longitudinal Culicoides hypersensitivity study. Icelandic horses (n = 16) were exported from Iceland at adult age.
Importation to the US took place in February of year 1 (arrow). The blood sampling time points (red circles) are shown for the two-year duration
of the study. Bold horizontal bars indicate the months of exposure to Culicoides in the environment of the horses, typically from mid-May to mid-
October. Clinical signs of allergy started during the second summer of Culicoides exposure
Fig. 2 Clinical signs of Culicoides hypersensitivity. Allergic horses
during the summer of year 2 are shown: (a) skin lesion on the face,
(b) hair loss and wounds on the tail and (c) mane, (d) allergic
wounds on the chest and (e) intermandibular space
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still elevated in the allergic group (p = 0.035; Fig. 4).
Afterwards, a trend of having overall higher Cul o 2 spe-
cific IgG3/5 antibodies was maintained in the allergic
compared to the non-allergic group but did not reach
significance anymore. This result supported the conclu-
sion that elevated Cul o 2 specific IgG3/5 antibodies
during or immediately after the first summer of expos-
ure to Culicoides predicted the development of CH in
these horses in the following summer.
None of the other allergen specific Ig isotypes
were serologically different between the allergic and
non-allergic groups between the summer of year 1
and February of year 2. Cul o 2 specific IgG1 and
IgG1/3 antibodies were slightly elevated in the al-
lergic group in August of year 1 but did not reach
significance. The Cul o 2 specific IgG1, IgG1/3,
IgG4/7, IgG6 and IgE responses are shown in
Additional file 2.
Allergen specific serum IgG responses indicative of
clinical allergy
The Culicoides allergen multiplex assay was used to
identify allergen specific Ig isotype that serologically dis-
tinguished allergic and non-allergic horses when clinical
allergy developed during the second Culicoides exposure
in the summer of year 2. In July of year 2, allergic horses
had higher serum IgG3/5 antibodies against the Cul o 3
degly allergen (p = 0.041) compared to non-allergic
horses (Fig. 5a). All of the remaining IgG isotype-
allergen combinations showed no difference between the
groups during this time point. The Cul o 3 degly specific
IgG1, IgG1/3, IgG4/7, IgG5, IgG6 and IgE responses are
shown in Additional file 3.
In the late fall of year 2, clinical signs of allergy re-
solved. Despite the absence of clinical signs in December
of year 2, allergic horses still maintained higher serum
IgG3/5 antibodies against Cul o 3 degly allergen than
Fig. 3 Clinical allergy scores in adult Icelandic horses during the first two years of natural exposure to Culicoides midges. a) Sixteen horses were
exported from Iceland to the US in the winter (February) of year 1 and were all kept in the same environment with natural Culicoides exposure
during the summer until the end of year 2. The severity of clinical allergy was evaluated by clinical allergy scoring. In the summer of year 2, nine
horses became allergic while seven horses remained non-allergic. The graphs show means and standard errors of the monthly allergy scores. The
dotted line shows the established cut-off value of the allergy scoring system. b) Comparison of the average monthly low and high temperatures
in the environment of the horses during the first and second year of Culicoides exposure revealed similar temperature curves in both years
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non-allergic horses (p = 0.043) (Fig. 5a). In addition, a
significant increase in serum IgG5 values against Cul o 2
(p = 0.035) was also observed in allergic horses in De-
cember of year 2 after clinical signs resolved (Fig. 5b).
Allergen specific IgE responses
We also used the allergen multiplex assay to detect
allergen specific IgE in serum. Overall, the allergen
specific IgE signals in serum obtained with this assay
were low throughout the study period compared to
the much higher IgG antibody responses. Differences
in allergen specific IgE responses between allergic and
non-allergic horses were not observed in these horses
during the first two years of Culicoides exposure. Cul
o2 and Cul o 3 degly specific IgE responses are
shown in Additional files 2 and 3.
Discussion
Culicoides midges feeding on horses are not present in
Iceland and, consequently, horses in Iceland are im-
munologically naïve to Culicoides allergens [5, 7, 16].
Here, we studied the development of clinical signs of
CH together with serological responses to nine Culi-
coides allergens in sixteen Icelandic horses that were
imported to the US in February 2012 and kept in a Culi-
coides endemic environment for the next two years with
natural exposure to the midges during the summer.
Clinical signs of allergy were evaluated using a clinical
scoring system [23] and horses were grouped in allergic
and non-allergic groups after they developed clinical al-
lergy or not in the second summer of Culicoides expos-
ure. Culicoides allergen specific antibodies in serum
were analyzed using a newly developed allergen multi-
plex assay before, during, and after horses showed clin-
ical signs of CH for the first time.
In previous studies, serological responses were evalu-
ated after horses showed clinical allergy in serum sam-
ples typically collected during Culicoides exposure [6, 7,
24–27]. In contrast, our approach used a uniquely con-
trolled horse CH model and also analyzed allergen spe-
cific Ig isotypes in serum of pre-symptomatic horses and
during seasons with and without Culicoides exposure.
To the best of our knowledge, this is the first study look-
ing prospectively at serological responses during allergy
development in CH.
In our study group, clinical signs of CH developed in
56% of the horses in the second summer of Culicoides ex-
posure which was similar to previous studies on exported
horses [5, 7]. The absence of clinical signs of allergy in the
first summer was not unexpected because IgE-mediated
immune responses often need some time to develop and
mast cell sensitization needs to occur prior to the develop-
ment of clinical allergy [3, 4]. Several reports confirmed
sensitization to Culicoides allergens by intradermal testing
and showed that sensitization often occurs during the first
season of Culicoides exposure with many of the sensitized
horses remaining non-allergic in the following years [4, 5,
28–30]. Consequently, intradermal testing and
sensitization are not reliable predictors whether a horse
will develop allergy in the future or not. Thus, the identifi-
cation of an allergic horse prior to the onset of clinical al-
lergy is still a challenge.
One important finding in our prospective study was
the identification of a potential predictive biomarker of
Fig. 4 Cul o 2 specific IgG3/5 antibodies in serum of allergic and non-allergic horses. IgG3/5 antibodies in serum of allergic (n = 9) and non-
allergic (n = 7) horses were measured using a Culicoides allergen multiplex assay. Horses were imported to the US in the beginning of year 1
(arrow). The areas surrounded by dotted lines represent the natural exposure times to Culicoides midges during the two-year study period. MFI =
median fluorescence intensity
Raza et al. BMC Veterinary Research          (2020) 16:283 Page 5 of 12
CH after initial sensitization to Culicoides allergens but
before signs of clinical allergy developed. Horses that de-
veloped clinical allergy, had higher Cul o 2 specific
IgG3/5 serum antibody amounts than the non-allergic
group in summer and fall of the first year in the US and
this trend continued through the following winter. Cul o
2 specific IgG3/5 was detected in these horses several
months before onset of clinical allergy and as early as
three months following first exposure to Culicoides
allergens.
A reliable serological marker, that allows the identifi-
cation of horses at risk of becoming allergic while they
are still clinically healthy, will open the door for the
development of novel targeted preventive and thera-
peutic strategies that can interfere earlier and more ef-
fectively with the immune imbalance against Culicoides
allergens. Currently, a causal treatment for CH is miss-
ing. Available treatments are given at a late stage after
sensitization occurred, the immune response to the al-
lergen clearly dysregulated, and becomes obvious as clin-
ical disease [5, 9]. Thus far, a number of attempts were
made to desensitize horses with allergen specific im-
munotherapy with low or inconsistent success [31–36].
Allergen immunotherapy in humans and studies in
mouse models highlighted the importance of the early
disease stage for successful therapeutic intervention and
Fig. 5 Allergen specific IgG3/5 and IgG5 responses against deglycosylated Cul o 3 and Cul o 2. IgG3/5 and IgG5 antibodies were measured using
a Culicoides allergen multiplex assays. Longitudinal data representing (a) Cul o 3 specific IgG3/5 antibodies and (b) Cul o 2 specific IgG5
antibodies in serum of allergic (n = 9) and non-allergic (n = 7) horses during the two-year study period. The arrow shows the time of import of
the horses to the US. The areas within the dotted lines indicate times of natural exposure to Culicoides midges. MFI = median
fluorescence intensity
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the development of allergen tolerance [37–41]. A pre-
dictive biomarker for CH would be advantageous for
transforming therapeutic interventions and the search
for a cure to this common allergic dermatitis of horses.
Nevertheless, the identification of Cul o 2 specific
IgG3/5 was performed in a small number of horses liv-
ing in one environment and under controlled conditions
in respect to their nutrition, vaccination, deworming and
other possible confounders of CH. Thus, this study is a
proof-of-principle approach showing that predictive bio-
markers can likely be detected for CH using modern
sensitive technologies with allergen and isotype specific
approaches. Thus, Cul o 2 specific IgG3/5 as a predictive
biomarker requires further evaluation by using larger
numbers of horses living in different environmental and
housing conditions before it could be used as a more
universal predictive marker for CH. We clearly observed
some overlap in Cul o 2 specific IgG3/5 antibody
amounts in allergic and non-allergic groups. This likely
means that a future validated predictive biomarker assay
for CH may need to have a high cut-off value to exclude
all future healthy horses. Consequently, such an assay
will not identify all horses that will develop future al-
lergy. However, the results shown here indicate that the
early identification of high values of Cul o 2 specific
IgG3/5 could have value as a biomarker in a validated
biomarker assay to identify future allergic horses above
the assay’s cut-off value and range of serological overlap.
These high-risk horses could become the target popula-
tion for preventive and early allergen immunotherapy.
Currently, the major Culicoides allergens causing CH
in the Northeastern US are unknown. Horses are ex-
posed to many Culicoides salivary proteins, but only a
few of these proteins will cause the degree of mast cell
degranulation that leads to CH. Therefore, identification
of disease relevant allergens will allow more specific
diagnosis and treatment in the future. Out of nine po-
tential Culicoides allergens tested in our approach, only
two, Cul o 2 and Cul o 3 degly, resulted in significant
differences in serological responses between the allergic
and non-allergic groups. Cul o 3 responses showed a
similar pattern as those to Cul o 3 degly (data not
shown). Previous studies in allergic horses in different
countries in Europe also identified Cul o 3 and Cul o 2
as major Culicoides allergens along with Cul s 1, Cul n 4
and Cul n 8 [6, 7, 42, 43]. Our data suggest that Cul o 2
and Cul o 3 also provide relevant diagnostic and possibly
therapeutic allergens against CH in the Northeastern
US. Although C. obsoletus has been described in Europe
and not in the US, C. sonorensis is prevalent in the
Northeast US [6]. It is thus likely that the immunogenic
structures of Cul o 2 and Cul o 3 equivalents of Culi-
coides midges at our location are shared by different
Culicoides species including those prevalent in Europe.
In conclusion, both Cul o 2 and Cul o 3 have been re-
ported as major allergens of Culicoides and are likely
causing CH in different countries and continents.
In this study, we did not detect any serological differ-
ence of the latter allergic and non-allergic horses before
they were imported to the US. This was an expected find-
ing and coincides with previous studies showing Icelandic
horses not reacting to intradermal Culicoides allergen in-
jections while in Iceland [7, 16]. However, Ziegler et al. [7]
found higher serum Cul o 3 specific IgG5 levels prior to
their first exposure to Culicoides in horses from Iceland
that were imported to Europe and later became allergic. It
remains to be elucidated how Cul o 3 specific antibodies
can develop in the absence of Culicoides exposure. In our
study, both groups of horses maintained similar Cul o 3
specific IgG5 amounts during year 1 of the observation
period, suggesting that other confounders or regional in-
fluences may have modified Cul o 3 specific IgG5 antibody
measurements prior to the first Culicoides exposure in the
former study by Ziegler et al. [7].
Clinical signs of allergy started to resolve at the end of
Culicoides exposure and completely resolve during win-
ter months in most horses. Simultaneously, significantly
increased Cul o 3 specific IgG3/5 and Cul o 2 specific
IgG5 were detected in allergic horses during late fall of
year 2. This suggested that IgG antibodies provide a tool
for detection of allergen specific immune responses be-
yond the actual exposure to Culicoides and distinguish
allergic from non-allergic horses during the non-
symptomatic phase that is currently lacking for CH. It is
also noteworthy that IgG5 and IgG3 are the two IgG iso-
types of the horse that have been associated with re-
sponses to extracellular pathogens and thus are most
likely linked to T helper 2 and IL-4 mediated immune
responses and precede IgE development in horses [44].
Surprisingly, allergen specific IgE levels in serum
remained still very low during the first two years of Culi-
coides exposure when tested with our sensitive multiplex
technique. What can be the reason for the relatively low
IgE measurements in allergic horses? One reason could
be that the total IgE concentration in serum is in the
high ng/ml to low μg/ml range while most IgG isotypes
occur in mg/ml concentrations [3]. Allergen specific IgE
and IgG isotypes are also just a small but variable por-
tion of the total serum antibody pool. Other studies have
shown that allergen specific IgE levels increase with sub-
sequent years of Culicoides exposure [7, 45] suggesting
that circulating allergen-specific IgE amounts in serum
may indeed still be quite low during the first and second
year of Culicoides exposure. In addition, allergen specific
IgG and IgE antibodies in serum compete for the bind-
ing to the allergen in the assay. Here, we have shown
very high Cul o 2 and Cul o 3 IgG, and especially IgG5
and IgG3/5, amounts during the Culicoides exposure
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season. If serum is used as a sample, these IgG anti-
bodies take up many allergen binding spaces in the
assay. For example, if Cul o 2 coupled beads are repre-
senting the assay’s matrix, only a small proportion of the
Cul o 2 allergen is available for Cul o 2 specific IgE bind-
ing corresponding to the relative portions of Cul o 2
specific IgE and IgG isotypes in the sample. As higher
the IgE proportion as more likely it is that the IgE that
bound to the Cul o 2 bead reaches the limit of detection
of the IgE detection assay (few ng/ml Cul o 2 specific
IgE). This happened in a few horses, as indicated by the
large error bars in the IgE figures in the article, but not
consistently in the whole group. However, allergen spe-
cific IgG in serum will always by far exceed allergen spe-
cific IgE amounts. Competition of binding site in
serological assays is a general problem of allergy diag-
nostics and has been recognized previously [2]. It is a
major weakness of allergen specific IgE detection in
serum samples. Allergen specific IgG isotype measure-
ments using allergen-isotype combinations that can dis-
tinguish allergic from non-allergic horses could help to
improve serological allergy diagnostics.
Conclusions
Out of nine allergens tested in this study we identified
two, Cul o 2 and Cul o 3, that shared cross-reactive epi-
topes with the Culicoides species in the Northeast US
and were valuable diagnostic tools to distinguish allergic
and non-allergic horses. Based on previous findings from
other groups in Europe and our US data shown here,
Cul o 2 and Cul o 3 are likely major Culicoides allergens.
These two allergens, in combination with IgG3/5 and
IgG5 isotype evaluation, can be used to confirm the clin-
ical diagnosis of CH and the allergen(s) responsible for
clinical disease. In addition, we found the first evidence
for a novel predictive biomarker for CH, Cul o 2 specific
IgG3/5 that identified horses prior to the development
of clinical allergy after they were exposed to Culicoides.
Methods
Horses and natural allergy model
Fifteen Icelandic mares and one stallion were purchased
in Iceland from private owners. In February 2012, all 15
mares were pregnant and exported together with the
stallion from Iceland to the US. At the time of import to
the US, the mares were 5 to 13 years of age (median 8
years) and the stallion was 16 years old. Prior to the ex-
port date of the horses Culicoides had never been de-
tected in Iceland and CH was never reported in Iceland.
The immune system of the horses was thus considered
naïve to Culicoides exposure by the time they entered
the US. After arriving in the US, the horses were directly
transported to Cornell University, where importation
quarantine was performed under USDA-APHIS supervi-
sion as previously described [46].
Afterwards, the horses were released to a pasture
area at Cornell University and were kept there as a
herd without contact to other horses for the following
two years. During the summer months, all horses
were naturally exposed to Culicoides which are en-
demic in the environment from mid-May to mid-
October during the first and second summer of the
study period. This was confirmed by collecting
Culicoides from the environment of the horses as pre-
viously described [6]. The wing pattern of Culicoides
at Cornell University did not match any of the pat-
tern reported earlier [47]. Horses lived outside 24/7
all year long with free access to running sheds, water
and mineral salt blocks. They were all on the same
diet composed of grass hay ad libitum during the
winter months and free pasture grazing during the
summer.
All mares foaled in June of the first summer (2012),
were afterwards covered by natural breeding by the same
stallion, and all 15 mares foaled again in June/July of the
second summer (2013). In both years, the mares foaled
without any complications and all foals were healthy. All
adult horses were simultaneously vaccinated and
dewormed as a group. Vaccinations were given against
Rabies, Tetanus, West Nile virus, Eastern and Western
Encephalitis virus in both years and against equine herpes-
virus in the year 2. Deworming was performed in Decem-
ber 2011 prior to exportation from Iceland and then at
Cornell University in March, August and December of
2012 and 2013. The horses did not receive any other
treatments.
Clinical scoring, allergy group assignment, and
environmental recording
A clinical allergy scoring system was previously de-
scribed and validated [23] and was used throughout this
project to evaluate pruritus, alopecia, and dermatitis
(Table 1). A clinical score was obtained from all horses
3–5 times per month and resulted in an average
monthly score for each individual horse. To be assigned
to the allergic group a horse had to have at least one
monthly clinical score of > 3 including a skin irritation/
dermatitis score of 1 or higher.
Daily maximal (high) and minimal (low) outside tem-
peratures were recorded throughout the study to deter-
mine if any environmental temperature differences
occurred in the two years of the study that could have in-
fluenced a variation of Culicoides activity. The daily tem-
peratures were used to calculate the average monthly high
and low temperatures. The average monthly temperatures
were then compared between years 1 and 2 to provide jus-
tification that the occurrence of clinical signs of CH in
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year 2 was not influenced by environmental temperature
differences between the two years of the study period.
Blood sampling
Blood samples were collected from the jugular vein with
a vacutainer collection system without coagulant and an
18-gauge needle. Blood samples were allowed to clot for
serum collection and were then centrifuged at 700 x g
for 10 min. The serum from each sample was harvested,
frozen, and stored at − 20 °C until the analysis for Culi-
coides specific antibodies was performed. Serum samples
collected at seven different time points were analysed for
this project (Fig. 1). Samples were taken: 1) prior to im-
portation to the US while the horses were still in
Iceland; 2) post importation to the US and prior to
the 1st Culicoides exposure (March, year 1); 3) during
the 1st Culicoides exposure (August, year 1); 4) in fall (No-
vember, year 1) and 5) winter after the 1st Culicoides ex-
posure (February, year 2); 6) during the 2nd Culicoides
exposure (July, year 2); and 7) in fall post 2nd Culicoides
exposure (December, year 2). All animal procedures were
approved by the Cornell University Institutional Animal
Care and Use Committee (protocol #2011–0011).
Allergens
Nine potential Culicoides allergens were included for
antibody testing in serum (Table 2). Out of several re-
ported potential allergens, the selection of allergens for
antibody testing was made based on information from
these reports on their ability to distinguish serological
responses in allergic and non-allergic horses [6–9, 19,
21] and the expression of sufficient allergen amounts as
soluble recombinant proteins. C. sonorensis allergens Cul
s 1 (AY603565) and Cul s D7 (AY603569) were
expressed in E. coli as previously described for other
proteins [48]. C. nubeculosus allergens Cul n 3
(HM145952) and Cul n 4 (HM145952) were expressed
in transgenic barley [49], and Cul n 8 (HM145956) in
Pichia pastoris. C. obsoletus allergens Cul o 2
(KC339672) and Cul o 3 (KC339673) were also
expressed in Pichia pastoris. Cul o 3 as well as Cul o 2
sequences each comprised two potential asparagine (N)-
glycosylation sites and were detected to be glycosylated
by Pichia. The native Cul o 3 and Cul o 2 variants repre-
sented the protein derived from the codon-optimized
gene sequences with Pichia specific N-glycosylation pat-
tern, while enzymatic deglycosylation delivered a variant
of Cul o 3 (Cul o 3 degly) without the glycans attached.
In addition, C. obsoletus apyrase (MN123717) was
expressed in insect cells (sf+).
Coupling of allergens to fluorescent-beads
Fluorescent color-coded microsphere beads (Luminex
Corp., Austin, TX) were coupled with nine potential
Culicoides allergens as outlined in Table 2. A total of
5 × 106 beads were coupled with 100 μg of the respective
allergen using a bead coupling procedure previously
described in detail [50].
Culicoides allergen multiplex assay
Allergen specific Ig isotypes in horse serum were quanti-
fied using a Luminex system (Luminex Corp., Austin,
TX). Each assay was multiplexed with nine different
color-coded beads coupled with an individual Culicoides
allergen (Table 2) as described above. For isotype meas-
urement, IgE and six IgG isotypes were detected
Table 1 Clinical scoring system for seasonal Culicoides hypersensitivity in horses used for the longitudinal evaluation of clinical signs
of allergy
Clinical sign Grade Score Maximal score
Pruritus No mane or tail scratching 0
Mild mane and/or tail scratching 1
Moderate mane and/or tail scratching 2
Intense mane and tail scratching 3 3
Alopecia None 0
Few broken hairs one location 1
Several locations with broken hairs 2
Moderate hair loss, mane or tail 3
Severe hair loss, mane and tail 4 4
Skin irritation/dermatitis No skin irritation 0
Mild dermatitis, one location 1
Moderate dermatitis, several locations 2
Dermatitis with skin lesions 3 3
Total score 10
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separately by preparing multiple copies of the sample
plates. The following biotinylated monoclonal anti-
equine isotype specific antibodies were used for detec-
tion: anti-IgE clone 134 [51], anti-IgG1 clone CVS45
[52], anti-IgG1/3 clone 159 [53], anti-IgG4/7 clone
CVS39 [52], anti-IgG5 clone 416 [53], anti-IgG3/5 clone
586 [53], and anti-IgG6 clone 267 [53].
For the assay run, Millipore Multiscreen plates (Milli-
pore, Danvers, MA) were soaked with PBS-T (0.05%
Tween20 in PBS) for 5 min. Then, the buffer was aspi-
rated using an EL X 50 plate washer (Biotek Instruments
Inc., Winooski, VT). Undiluted serum samples were ap-
plied to the wells followed by bead mix solution with a
total of 5 × 103 beads per allergen and microtiter well in
PBN buffer (1% BSA and 0.05% sodium azide in PBS,
pH 7.4). The plates were covered with a foil to be
protected from light, incubated for 30 min at room
temperature on a shaker, and washed afterwards. Then,
the different biotinylated anti-isotype detection anti-
bodies were added to the plates and incubated for 30
min on the shaker at room temperature. All detection
antibodies were diluted 1:500 in PBN. After incubation,
plates were washed again. Streptavidin-phycoerythrin
(Invitrogen, Carlsbad, CA) diluted 1:100 in PBN was
added to the plates, incubated for 30 min on the shaker
at room temperature, and then washed. Beads were re-
suspended in 100 μl of PBN and incubated for 15 min on
the shaker at room temperature. Finally, the assay was
analysed in a Luminex 200 instrument (Luminex Corp.,
Austin, TX).
Statistical analysis
The average monthly clinical scores during the two-year
time period were compared between allergic and non-
allergic groups by repeated-measures ANOVA using
Sidak multiple comparison tests and using GraphPad
Prism 6 for Mac OS X, version 6 f. The average monthly
low and high environmental temperatures were normally
distributed (D’Agostino & Pearson normality tests) and
were compared by paired t-tests. The IgE and IgG aller-
gen multiplex result analyses were conducted in R soft-
ware (R Project for Statistical Computing [http://www.r-
project.org/]). P values of 0.05 were considered statisti-
cally significant. The clinical presentation of allergy
(present/absent) was determined in the second summer
and horses were classified as clinically allergic or non-
allergic. Seven isotype antibodies were used to measure
serum antibodies against each of nine potential Culi-
coides allergens, producing 63 (7 × 9) isotype-allergen
variables [Additional file 1]. Statistical analyses were
conducted on subsets of data corresponding to the four
study questions. For question 1 we used a subset of data
from August and November of year 1, and February of
year 2, while for question 2 we used data from samples
taken in October prior to importation and March of year
1. For questions 3 and 4, we used a subset of data
acquired in July and December of year 2, respectively.
Statistical analysis started with the screening of the indi-
vidual 63 isotype-allergen variables to identify those that
were able to differentiate among allergic and non-
allergic horses. The screening involved (i) visual examin-
ation of boxplots and (ii) statistical testing using a
Mann-Whitney test, which was selected due to a rela-
tively small sample size and the non-parametric nature
of the test. Isotype-allergen variables with Mann-
Whitney p-values < 0.05 were selected for further uni-
variable testing using logistic regression [Additional file
1]. In testing the hypotheses underlying questions 1 and
2, the interest was in evaluating the combined effect of
date and isotype-allergen variable using an interaction
term. The effect of date alone was tested but was not
significant. In the hypothesis testing as part of questions,
3 and 4 multivariable models were developed but none
improved the model fit. Likewise, multivariable models
with more than one isotype-allergen variable were tested
but none improved the model fit. The model fit was
evaluated based on the Likelihood Ratio test and
Akaike’s Information Criterion.
Table 2 Culicoides allergens used for bead coupling to provide the allergen specific matrix of the allergen multiplex assay
Culicoides Species Allergen Fluorescent bead No. Origin Expression system
C. obsoletus Cul o 2 40 Germany Pichia pastoris
Cul o 3 a 39 Germany Pichia pastoris
Cul o 3 (degly) a 37 Germany Pichia pastoris
Apyrase 41 Germany Insect cells (sf+)
C. nubeculosus Cul n 3 36 Iceland Barley
Cul n 4 34 Iceland Barley
Cul n 8 42 Germany Pichia pastoris
C. sonorensis Cul s 1 33 Cornell E. coli
Cul s D7 38 Cornell E. coli
a Cul o 3 was used as originally expressed in Pichia pastoris. The same protein was also used in a deglycosylated form
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Additional file 1. Results of Mann-Whitney test in initial analysis of all
data points. Significant combinations from four questions asked are
highlighted and were further analyzed by logistic regression.
Additional file 2. Cul o 2 specific antibodies in serum of allergic and
non-allergic horses. Antibodies in serum of allergic (n = 9) and non-
allergic (n = 7) horses were determined using a Culicoides allergen multi-
plex assay. (A) Cul o 2 specific IgG1, (B) IgG1/3, (C) IgG4/7, (D) IgG6, and
(E) IgE. Horses were imported to the US in the beginning of year 1
(arrow). The dotted lines represent the natural exposure times to Culi-
coides midges during the two-year study period. MFI = median fluores-
cence intensity.
Additional file 3. Cul o 3 specific antibodies responses in serum of
allergic and non-allergic horses. Longitudinal data representing (A) Cul o
3 specific IgG1, (B) IgG1/3 (C) IgG4/7 (D) IgG5, (E) IgG6, and (F) IgE anti-
bodies in serum of allergic (n = 9) and non-allergic (n = 7) horses during
the two-year study period. The arrow shows the time of import of the
horses to the US. The dotted lines indicate natural exposure to Culicoides
midges. MFI = median fluorescence intensity.
Additional file 4. Original data file.
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